Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
highlights<br />
Opening of the first The Body Shop stores in Egypt<br />
and Slovakia, and strategic acquisition of<br />
franchisees in Spain.<br />
Development of three new Community Trade<br />
supplier relationships in Kenya, Samoa and<br />
Ecuador.<br />
Launch of Nature’s Minerals , a make-up range<br />
with 100% minerals, fragrance and preservative<br />
free, offering the highest sun protection factor in<br />
its category.<br />
Introduction of 100% recycled PET bottles.<br />
Since 2003, The Body Shop has raised nearly £1.2<br />
million to help women who are victims of domestic<br />
violence, as part of the Stop Violence in the Home<br />
campaign. In addition, the RSPCA (Royal Society for<br />
the Prevention of Cruelty to Animals) awarded it<br />
a prize for its longstanding commitment to<br />
animal welfare. In 2009, the brand will publish its<br />
Values Report, following a review by independent<br />
experts.<br />
—THE BODY SHOP<br />
100% recycled<br />
PET bottles.<br />
GALDERMA<br />
Science in the service of dermatologists<br />
Dedicated exclusively to dermatology and with innovation and research at the<br />
heart of its strategy, Galderma’s ambition is to be recognised as the most<br />
competent and innovative company in its field.<br />
Galderma experienced an exceptional year and<br />
continued to gain market share in its traditional<br />
markets, particularly in North America where<br />
sales increased by 18.5%. The main growth<br />
drivers were Differin ® and Epiduo (acne),<br />
Rozex ® /Metro ® and Oracea ® (rosacea), Clobex ®<br />
(psoriasis), Dysport ® (frown lines) and Cetaphil ®<br />
(therapeutic skincare line).<br />
Through the acquisition of CollaGenex in the<br />
United States, Galderma has enhanced its<br />
product portfolio with Oracea ® , the first oral<br />
treatment for rosacea authorised by the FDA<br />
(Food and Drug Administration), as well as<br />
two topical products which are under<br />
development.<br />
In Japan, the second largest dermatology<br />
market in the world, the launch of Differin ®<br />
represented an important landmark. This<br />
product for acne is the first topical retinoid<br />
approved in the country.<br />
Epiduo has successfully gained ground in Latin<br />
America and Europe.<br />
Galderma has entered the corrective and<br />
aesthetic dermatology market with the launch<br />
of Dysport ® in Latin America. The European<br />
launch, under the Azzalure ® brand name, is<br />
scheduled for 2009.<br />
Some fifty patents have been filed to protect<br />
innovation and numerous products have been<br />
registered.<br />
+17.1%<br />
sales growth like-for-like in <strong>2008</strong><br />
In 2009, Galderma will continue its worldwide rollout<br />
of Epiduo , in the United States in particular,<br />
where it was approved at the end of <strong>2008</strong>. Vectical ® ,<br />
for the treatment of psoriasis, will enhance the<br />
American subsidiary’s product range. Several<br />
strategic products will be launched in Europe:<br />
Oracea ® , Clobex ® Shampoo and Azzalure ® .<br />
—GALDERMA<br />
Differin ® .<br />
€854 million<br />
in sales generated in <strong>2008</strong><br />
—GALDERMA<br />
Epiduo GALDERMA<br />
.<br />
17